

THE PUBLIC'S HEALTH

Newsletter for Medical Professionals in Los Angeles County

Volume 3 • Number 7

September 2003

Don't be quick to blame spiders for those "spider bite" wounds!

It is a well-publicized and frequently cited fact that bites (envenomation) by the brown recluse spider, *Loxosceles reclusa*, will produce dermonecrotic wounds. In comparison, far less is known by both the general public and the medical community about the recognized range of the spider, the inconsequential resolution of most brown recluse spider bites, and the reticent nature of the spider. Also important, but often overlooked, is the propensity of *Loxosceles* sp. to be present in often surprising numbers in homes within the endemic range with no recorded history of bites despite years of co-habitation.^{1,2}

The endemic range of the brown recluse spider is southeastern Nebraska through Texas, east to Georgia and southernmost Ohio. Ten additional



The brown recluse spider (above) looks very similar to many of the large spiders found in Los Angeles County.

Loxosceles species are native to the southwestern U.S. deserts, and two non-native species are found within the continental U.S., but are rare and sporadic in distribution.³ It has been repeatedly shown that all native species are known to be

abundant in their respective ranges, and research has indicated that due to the necrotic capabilities of the venom, all species of *Loxosceles* should be considered to have public health significance.

No established populations of the brown recluse spider have ever been documented within California.

Although California is well outside the recognized range of the brown recluse spider, a few verified specimens (<10) have been collected throughout the state. Most have been attributed to accidental transportation with goods delivered from an area within the spider's endemic distribution.⁴ Despite an established commercial and private translocation of goods from within the recognized range, no established populations of the brown recluse spider have ever been documented within the state.

Los Angeles County lies within the range of one *Loxosceles* species and is known to have limited populations of a non-native species as well. The sparsely populated arid regions of our county are home to the desert recluse, *L. deserta*, where spiders are found

Continued on page 4

Is that spider bite actually MRSA?

Misdiagnosis of methicillin resistant *Staphylococcus aureus* (MRSA) as due to spiders bites has been occurring in Los Angeles County with increasing frequency. The Los Angeles County Department of Health Services has investigated MRSA outbreaks originally and erroneously believed due to spider bites (see the February 2003 issue of **The Public's Health** available at: www.lapublichealth.org/wwwfiles/ph/ph/ph/TPH0203.pdf). This misdiagnosis not only impeded proper treatment but facilitated the spread of this infection.

**Information about MRSA infection is available at: www.lapublichealth.org/acd/MRSA.htm
or by calling Acute Communicable Disease Control: 213-240-7941**

See related article about Pediatric MRSA page 4

THE PUBLIC'S HEALTH

is published by:



COUNTY OF LOS ANGELES
DEPARTMENT OF HEALTH SERVICES
Public Health

313 North Figueroa Street, Room 212
Los Angeles, California 90012

The Public's Health can be automatically e-mailed to you (as a PDF document) each month. To subscribe, please visit <http://www.ladhs.org/listserv> and enter your e-mail address. Select "Department Newsletters" and then "**The Public's Health**." You are welcome to make copies of this newsletter. To view this publication online – and obtain a variety of public health information and data – visit our website: www.lapublichealth.org



LOS ANGELES COUNTY BOARD OF SUPERVISORS:

Gloria Molina, *First District*
Yvonne Brathwaite Burke, *Second District*
Zev Yaroslavsky, *Third District*
Don Knabe, *Fourth District*
Michael D. Antonovich, *Fifth District*

DEPARTMENT OF HEALTH SERVICES:

Thomas L. Garthwaite, MD
Director and Chief Medical Officer
Fred Leaf
Chief Operating Officer
Jonathan E. Fielding, MD, MPH
Director of Public Health and County Health Officer
James Houghton, MD, MPH
Medical Director, Public Health
Laurene Mascola, MD, MPH
Chief, Acute Communicable Disease Control

EDITORIAL BOARD:

James DeCarli, MPH, CHES
Maria Iacobo, MS
Anna Inencion, MPH
Eleanor Long, MSPH
Robert Miodovski, MPH
Jorge Montoya, PhD
Harold Sterker, MPH

Sadina Reynaldo, PhD, *Editor*
Tony Taweessup, *Design & Productions*
Teresa Graves, *Administration*

CONTRIBUTORS TO THIS ISSUE:

Elizabeth Bancroft, MD, SM
Director, Hospital Infections, Bloodborne Pathogens and Antimicrobial Resistance Unit, Acute Communicable Disease Control

Susan Hathaway, RN, MPH
Public Health Nurse, Acute Communicable Disease Control

Ben Techagaiciyawanis, MPH, CHES
Senior Health Educator, Acute Communicable Disease Control

Gail VanGordon, MS, REHS
Public Health Entomologist, Vector Management Program

Notice of correction: Hospitalized varicella reportable in Los Angeles County

The June 2003 issue of **The Public's Health*** announced the addition of hospitalized varicella cases to the list of reportable diseases and illnesses in Los Angeles County. This addition was described as mandated by the California Department of Health Services, but is actually a "suggested" change to the existing reporting standards. The Los Angeles County Department of Health Services has implemented this reporting requirement due to the high rates of morbidity resulting from this disease and the need to better monitor this vaccine-preventable illness. Hospitalized cases should be reported within 7 days of identification using the standard Confidential Morbidity Report (CMR) available at: www.lapublichealth.org/acd/reports/Reporting%20Forms/CMR.pdf.

Fatal cases of varicella should be reported immediately by phone to Acute Communicable Disease Control: 213-240-7941.

* This issue is available at: www.lapublichealth.org/wwwfiles/ph/ph/ph/TPH_June_2003.pdf

Alcohol and Drug Addiction Recovery Month Activities

The Los Angeles County Board of Supervisors has recognized September as "National Alcohol and Drug Addiction Recovery Month" – a time to educate the public that addiction is a chronic, but treatable, public health problem that can affect all residents. Several educational and recreational events are being sponsored by the county's Alcohol and Drug Program Administration (ADPA) and its many partners.

October 11, 2003, 9 am- 3 pm.

Al-Impics 2003 –Healthy and Free in 2003

Celebrate wellness and sobriety and share the life-enriching experiences associated with the recovery process. Recovering persons, families and friends are encouraged to join this recreational event which includes: competitive track and field, social events for all ages, games for children and teens, entertainment and health education exhibits.

Location: Los Angeles Southwest College, 1600 Imperial Highway.

In partnership with more than 100 contracted prevention, treatment and recovery programs, ADPA offers referrals to alcohol and drug treatment at (800) 564-6600. The National Clearinghouse on Alcohol and Drug Information has information on national recovery month at www.recoverymonth.gov or call 1-800-729-6686.

Spiders (from page 1)

beneath wood piles and other debris. The South American recluse, often referred to as the "fiddle back" or "violin" spider, was inadvertently introduced into our county, and restricted populations were discovered in 1969 in a foothill foci, most notably in the cities of Alhambra and Sierra Madre. The spider was uncovered again in 1991 in downtown Los Angeles where an extensive survey revealed an extremely limited distribution within a 15 block area where the spiders were found to predominantly occupy dark, seldom used basements in commercial buildings. In all circumstances, there has never been a documented bite incident from within the established foci of either species.

Physicians in LA County should be cautious when implicating brown recluse spiders as the source of necrotic lesions and should first consider the many other probable causes for the condition.

Despite this limited distribution of *Loxosceles* within our county, the general population regularly claims bites by the brown recluse spider,

and the medical community continues to fan the flame by attributing spider bites as a regular source of skin lesions. This diagnosis is frequently provided despite the fact that no spider was observed inflicting a bite, or a common brown colored spider is collected from the general vicinity of the proposed bite incident and misidentified by the physician, the patient, or a pest control technician.

Physicians in Los Angeles County should be cautious when implicating brown recluse spiders as the source of necrotic lesions and should first consider the many other probable causes for the condition


(see Table 1). If a spider is implicated, verification of the genus and species should be performed by a qualified entomologist (see below). The medical community should make a conscious effort whenever possible to dispel the enigma of the brown recluse spider in Los Angeles County. Additional information on the brown recluse spider is available at <http://spiders.ucr.edu/> or visit the Spider Myth Site at www.washington.edu/burkemuseum/spidermyth.index.html. 

Table 1. Conditions that can cause necrotic wounds and/or that have been misdiagnosed as brown recluse spider bites:⁴

- Infections with Staphylococcus or Streptococcus species
- Herpes simplex
- Herpes zoster
- Erythema multiforme
- Diabetic ulcer
- Lyme disease
- Fungal infection
- Pyoderma gangrenosum
- Lymphomatoid papulosis
- Chemical burn
- Poison ivy/oak dermatitis
- Squamous cell carcinoma
- Localized vasculitis
- Syphilitic chancre

For questions regarding spider bites and spider identification, contact the Vector Management Program at: 626-430-5450.

References:

1. Vetter, R. S. and D. K. Barger. An infestation of 2,055 brown recluse spiders and no envenomations in a Kansas home: implications for bite diagnoses in nonendemic areas. *J Med Ent* 2002; 39:948-951.
2. Schenone, H., A. Rojas, H., Reyes, et al. Prevalence of *Loxosceles laeta* in houses in Central Chile. *Am J Trop Med Hyg* 1970; 19:564-567.
3. Gertsch, W. J. and F. Ennik. The spider genus *Loxosceles* in North America, Central America, and the West Indies (Araneae, Loxoscelidae). *Bull Am Mus Nat Hist* 1983; 175:264-360.
4. Vetter, R. S. Myth: idiopathic wounds are often due to brown recluse or other spider bites throughout the United States. *West J Med* 2000; 173:357-358.

Community-associated MRSA in hospitalized children: results from interim analysis

In response to the increase in community-associated methicillin-resistant *Staphylococcus aureus* (CAMRSA) infections reported in Los Angeles County, the Department of Health Services (DHS) added skin, soft tissue, and invasive MRSA infections to the list of local reportable diseases (as described previously in **The Public's Health**).¹ This reporting requirement is limited to infections among hospitalized children (<18 years) and excludes nosocomial (healthcare associated) infections unless part of an outbreak. The reporting period began May 5, 2003 and will end on November 7, 2003.

After 13 weeks of surveillance, 62 hospitalized cases have been reported to DHS. The patient population is a diverse group comprised of children from a variety of races and ethnicities (see Table). Their mean age is 6.9 years (median 5.5 years, range of 14 days to 17 years). Among cases where admitting diagnosis was indicated, the most common diagnosis was cellulitis, accounting for half of all reported illnesses. Moreover, these infections accounted for substantial illness; the average length of hospitalization was 7 days (range of 1-33 days). All of the reported infections are resistant to β -lactam antibiotics. But in addition, the results of

One-fourth of interviewed guardians erroneously believed their child's infection was due to a spider or bug bite.

sensitivities provided by hospital labs indicate that most are also resistant to ciprofloxacin (89%) and levofloxacin (75%). Isolates are being collected for

CAMRSA infections among hospitalized children: Preliminary findings of interim reporting, Los Angeles County*

Gender (n=62)	
Female	56%
Male	44%
Race (n=39) [†]	
White	74%
African American	18%
Asian/Pacific Islander	5%
Other	3%
Ethnicity (n=39) [†]	
Hispanic	68% [‡]
Non-Hispanic	32%
Admitting Diagnosis (n=53) [†]	
Cellulitis	50%
Abcess	25%
Cellulitis and abcess	6%

* Data as of 8/25/03.

[†] Information not available for all reported cases.

[‡] According to 2000 census, 28% of the L.A. County population under 18 years are Hispanic.

analysis at the end of this study. These will be studied using pulsed-field gel electrophoresis (PFGE) to determine their relatedness, and additional tests will determine virulence factors.

Parent/caregiver surveys were also conducted to obtain broader information regarding these infections. To date, 43 of 62 guardians have been interviewed. Of 13 cases with treatment with known antibiotics before

Continued on page 5

The reporting of hospitalized pediatric CAMRSA cases will end on November 7th, 2003. Cases should be reported using a standard Confidential Morbidity Report (CMR) form (available at: www.lapublichealth.org/acd/reports/diseasePLUScmr.pdf) and may be reported directly to the Morbidity Unit (telephone 213-240-7821 or fax 888-397-3778).

DHS is also requesting that the antibiogram of the MRSA isolate be submitted with the CMR. The isolate should be sent to LAC Public Health Laboratory (313 North Figueroa Street, Los Angeles, CA 90012).

Questions regarding this reporting requirement can be addressed by calling Acute Communicable Disease Control at 213-240-7941.

Additional information about MRSA infection including guidelines for patients and healthcare providers regarding the diagnosis, prevention and treatment of community associated MRSA is available at: www.lapublichealth.org/acd/MRSA.htm.

MRSA in hospitalized children (from page 4)

hospitalization, nearly all (85%, n=11) were treated with β -lactam antibiotics which are not effective against this type of infection. Also of note, one-fourth of the interviewed guardians had initially, and erroneously, thought their child's infection was due to a spider or bug bite. Findings from these interviews also suggest that many of these infections had spread among members of their households: 24% reported that the affected child was exposed to another individual in the home with lesions during the month before the child's infection. And following the child's infection, 12% of contacts in the home also developed a

skin lesion. This demonstrates that an immediate, accurate, and effective diagnosis and treatment is necessary to limit the spread of these infections. The continued reporting of CAMRSA infections will be instrumental in the development and refinement of educational materials and recommendations for health care professionals. ¶

References:

1. Pediatric MRSA Interim Reporting. **The Public's Health**, May 2003, Vol. 3 No. 4. Available at: www.lapublichealth.org/www-files/ph/ph/TPH_May_2003.pdf

New Tuberculosis Treatment Guidelines

In February 2003, the new official joint statement for the treatment of tuberculosis by the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and the Infectious Disease Society of America (IDSA) was published in the *American Journal of Respiratory and Critical Care Medicine*. There are several additions to the new 60-page document in comparison to the previous one published in 1993. The California Tuberculosis Controllers Association (CTCA) also published a set of tuberculosis treatment guidelines in April 2003 based on the ATS/CDC/IDSA statement. The following are highlights of the revised recommendations:

- The responsibility for treatment is assumed by the public health program or private provider, not the patient.
- The initial treatment strategy utilizes patient-centered case management with an emphasis on directly observed therapy.
- Obtaining sputum cultures at the time of completion of the initial phase of therapy is emphasized to identify patients at increased risk of relapse.
- Patients with drug-susceptible pulmonary tuberculosis with cavitation noted on their initial chest film, and who have positive sputum cultures at the completion of 2 months of treatment, are recommended to have extended treatment.

- The roles of rifabutin, rifapentine, and the fluoroquinolones are discussed.
- Issues in therapy, such as drug administration, use of fixed-dose combination preparations, monitoring and management of adverse effects, and drug interactions are described.
- Considerations for special situations include: HIV infection, pediatric tuberculosis, extrapulmonary tuberculosis, culture-negative tuberculosis, pregnancy and breastfeeding, hepatic disease, and renal disease.
- Management of drug-resistant tuberculosis is discussed.
- Comparison between the new recommendations with those of the World Health Organization (WHO) and International Union Against Tuberculosis and Lung Diseases (IUATLD) and the Directly Observed Treatment, Short Course (DOTS) strategy are outlined.
- On-going research to improve treatment is reviewed.

The full treatment guidelines (American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. *Am J Respir Crit Care Med*, 2003; 167: 603-662) are available online at www.atsjournal.org. The CTCA guidelines can be found online at www.ctca.org. ¶

Update: Rabies Control and Prevention, 2003

The California Department of Health Services has recently revised its recommendations for rabies control and prevention. The full 2003 Compendium of Rabies Control and Prevention is available at: www.dhs.ca.gov/ps/dcdc/disb/pdf/2003%20CA%20Rabies%20Compendium.pdf or by calling the California Department of Health Services Veterinary Public Health Section (916-327-0332).

Of importance are the revised recommendations for human rabies postexposure prophylaxis (PEP). The essential components of rabies PEP are: immediate wound cleaning, treatment (i.e., tetanus and antibiotic prophylaxis as needed) and the appropriate administration of human rabies immune globulin (HRIG) and rabies vaccine. Persons who are bit-

ten by or have significant exposure to saliva or nervous system tissue of a confirmed rabid animal should begin rabies PEP **immediately**. In addition to the classic bite exposure (teeth penetrating skin), non-bite exposure, such as the saliva contamination of open wounds or scratches, has been documented and may constitute sufficient reason to consider rabies PEP. In addition, a person exposed to a **suspected** rabid animal should begin treatment if rabies testing on the animal is not immediately available.

The most important exposure to rabies in Los Angeles County is through bats. Rabies virus transmission can occur from very minor or even unrecognized bites. Bat bites may not leave any evident mark and often a patient may have limited recall of exposure which interferes with proper diagnosis of bat-based rabies. Healthcare providers should discourage all human contact with bats.

Beyond postexposure treatment, preexposure vaccination should be offered to all persons at increased risk of rabies exposure. This includes: veterinarians, animal handlers, animal control officers,

Continued on page 7

To obtain assistance with rabies treatment decisions, or to refer an uninsured patient for treatment, call Acute Communicable Disease Control 213-240-7941

Rabies Biologics — United States, 2003

Type	Product name	Manufacturer
Human Rabies Vaccine		
Human diploid cell vaccine (HDCV)		
· Intramuscular	Imovax® Rabies	Aventis Pasteur, Inc.
· Intradermal (<i>for pre-exposure ONLY</i>)	Imovax® Rabies I.D.	(800) 822-2463 www.aventispasteur.com
Purified chick embryo cell vaccine (PCEC)		
· Intramuscular (not approved for intradermal)	RabAvert™	Chiron Vaccines (800) 244-7668 www.rabavert.com
Rabies vaccine adsorbed (RVA)		
· Intramuscular (not approved for intradermal)	Rabies Vaccine Adsorbed (RVA)	Bioport Corporation (517) 327-1500 www.bioport.com
<i>(All three types of vaccine are considered equally efficacious and safe when used as indicated.)</i>		
Human Rabies Immune Globulin (HRIG)		
	BayRab™	Bayer Corporation Pharmaceutical Div. (800) 288-8370 www.bayer.com
	Imogam® Rabies-HT	Aventis Pasteur, Inc. (800) 822-2463 www.aventispasteur.com
<i>(Both types of HRIG are considered equally efficacious and safe when used as indicated.)</i>		

Rabies Control and Prevention Update (from page 6)

laboratory workers with potential exposure to rabies virus, and persons traveling to and spending time (e.g., >1 month) in foreign countries where rabies is endemic. Preexposure vaccination should also be considered for persons whose habits and hobbies may expose them to potentially rabid animals (e.g., dogs, cats, skunks, bats). The advantage of preexposure prophylaxis is protection of persons with unrecognized rabies exposure. In addition, it simplifies and saves money inherent in rabies postexposure treatment. This also may protect persons exposed in areas where immunizing products are not available or when treatment may be delayed (e.g., travelers). ☞

Reporting Animal Bites

Animal bites can cause serious injury, bacterial and viral infections, physical and psychological trauma, and even death. As such, it is critical to public health to obtain an accurate account of all animal bites that occur in our county.

Information for reporting animal bites is available by phone

877-747-2243 Rabies Hotline

or can be completed on-line through our secure website:

www.lapublichealth.org/vet/biteintro.htm



ANTIBIOTIC RESISTANCE INFORMATION CORNER

Effect of Amoxicillin-Clavulanate in Clinically Diagnosed Acute Rhinosinusitis: A Placebo-Controlled, Double-Blind, Randomized Trial in General Practice

Bucher HC, Tschudi P, Young J, et al. Arch Intern Med 2003;163:1793-1798.

Available at: <http://archinte.ama-assn.org/cgi/content/abstract/163/15/1793>

Acute rhinosinusitis is one of the most common diagnoses in primary care and most often caused by an uncomplicated viral infection. Much concern focuses on the overuse of antibiotics that are frequently prescribed for this condition. Results of this study among adults with suspected acute bacterial rhinosinusitis indicate that antibiotic treatment with amoxicillin-clavulanate offers no clinical benefit. No differences were found in the time to cure between amoxicillin-clavulanate (29.8% at 1 week; 76.6% at 2 weeks) and placebo groups (30.7% at 1 week; 74.0% at 2 weeks). Additionally, patients treated with amoxicillin-clavulanate were more likely to experience side effects of diarrhea and abdominal pain. Symptomatic treatment rather than antibiotic prescription is recommended for acute rhinosinusitis. Such measures can prevent unnecessary costs and reduce antibiotic-resistant strains in the community.

The Centers for Disease Control and Prevention (CDC) provides clinical practice guidelines for otitis media, rhinitis, sinusitis, and cough illness/bronchitis available online at: www.cdc.gov/drugresistance/community/technical.htm and at www.cdc.gov/drugresistance/technical/prevention_tools.htm

Other clinical practice guidelines can be found at the Infectious Diseases Society of America (IDSA) web site: www.idsociety.org or in major medical journals. ☞

West Nile Virus

With the rapid increase of WNV cases occurring in areas across the U.S., LA residents are reminded that their efforts to reduce mosquito breeding is more important than ever; eliminating sources of stagnant water which foster mosquitoes can help prevent WNV and other mosquito-borne diseases. The public is also encouraged to report dead birds which may identify the presence of WNV (1-877-747-2243).

For recorded information on West Nile Virus call: 800-975-4448 (English, Spanish, Thai, Korean, Mandarin Chinese, Vietnamese)

For questions regarding the reporting of WNV cases call: Acute Communicable Disease Control (213-240-7941)

or visit: www.lapublichealth.org/acd/VectorWestNile.htm

This Issue . . .

Spider Bites	1
Alcohol and Drug Addiction Recovery Activity	2
MRSA in Hospitalized Children	4
New Tuberculosis Treatment Guidelines	5
Rabies Control and Prevention Updates	6
Antibiotic Resistance Corner	7

THE PUBLIC'S HEALTH

Newsletter for Medical Professionals in Los Angeles County



313 North Figueroa Street, Room 212
Los Angeles, California 90012

Selected Reportable Diseases (Cases)¹ - May 2003

Disease	THIS PERIOD May 2003	SAME PERIOD LAST YEAR May 2002	YEAR TO DATE		YEAR END TOTALS		
			2003	2002	2002	2001	2000
AIDS ¹	262	132	1,069	673	1,787	1,354	1,648
Amebiasis	10	9	48	43	109	139	109
Campylobacteriosis	81	72	382	352	1,092	1,141	1,273
Chlamydial Infections	2,802	3,193	14,322	13,491	36,590	31,658	30,642
Encephalitis	8	7	25	24	63	41	49
Gonorrhea	650	610	2,869	2,984	7,985	7,468	7,212
Hepatitis Type A	29	53	156	249	482	542	839
Hepatitis Type B, Acute	5	2	24	13	27	44	65
Hepatitis Type C, Acute	1	0	1	0	3	1	28
Measles	0	0	0	0	0	8	5
Meningitis, viral/aseptic	46	38	217	231	669	530	491
Meningococcal Infections	1	2	16	27	46	58	53
Mumps	0	0	7	14	16	17	29
Non-gonococcal Urethritis (NGU)	116	126	564	537	1,398	1,343	1,575
Pertussis	5	9	67	64	167	103	102
Rubella	0	0	0	0	0	0	3
Salmonellosis	55	48	361	329	990	1,006	990
Shigellosis	26	49	346	236	922	684	849
Syphilis, primary & secondary	24	30	149	118	362	181	136
Syphilis, early latent (<1 yr.)	16	27	111	128	341	191	194
Tuberculosis	55	79	274	284	1,025	1,046	1,065
Typhoid fever, Acute	1	1	6	7	34	17	21

1. Case totals are interim and may vary following periodic updates of the database.

Data provided by DHS' Public Health programs: Acute Communicable Disease Control, HIV/Epidemiology, Sexually Transmitted Diseases, and Tuberculosis Control.